AbbVie Inc. (FRA:4AB)
Germany · Delayed Price · Currency is EUR | Market Cap | 300.59B |
| Revenue (ttm) | 49.67B |
| Net Income (ttm) | 3.17B |
| Shares Out | n/a |
| EPS (ttm) | 1.79 |
| PE Ratio | 94.82 |
| Forward PE | 15.14 |
| Dividend | 5.86 (3.45%) |
| Ex-Dividend Date | Jul 15, 2025 |
| Volume | 30 |
| Average Volume | 93 |
| Open | 170.80 |
| Previous Close | 170.80 |
| Day's Range | 170.00 - 170.80 |
| 52-Week Range | 147.00 - 203.05 |
| Beta | n/a |
| RSI | 62.14 |
| Earnings Date | Jul 25, 2025 |
About HashiCorp
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer... [Read more]
Financial Performance
In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.
Financial StatementsNews
AbbVie Inclusion In Medicare Drug Talks Fails To Justify Lawsuit, Court Rules
AbbVie Inc. (NYSE: ABBV), the manufacturer of Imbruvica, is at the center of a constitutional challenge to the federal government's new Drug Price Negotiation Program. Imbruvica was among the first 1...
Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79%
Genmab A/S (NASDAQ: GMAB) released results Thursday of the Phase 3 EPCORE FL-1 trial evaluating subcutaneous epcoritamab in combination with rituximab and lenalidomide (R2) versus R2 alone for adult ...
Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79%
Genmab A/S GMAB released results Thursday of the Phase 3 EPCORE FL-1 trial evaluating subcutaneous epcoritamab in combination with rituximab and lenalidomide (R2) versus R2 alone for adult patients wi...
Get Ready, JUVÉDERM® Day is Calling!
Allergan Aesthetics Celebrates Third Annual JUVÉDERM® Day with BOGO Gift Cards and $10,000 Sweepstakes Join Allē Today to Take Advantage of Limited-Time Offers, While Supplies Last IRVINE, Calif. , Au...
AbbVie (ABBV) Stock Signal: How Strong is the Double Top Formation? - 06 August 2025
An excellent return on equity and a growing presence in neuroscience have boosted this stock, but while valuations are sky-high, operating and profit margins are falling. What will happen after price ...
Allergan Aesthetics Unveils the New Faces of Natrelle® and Real Stories of Empowerment and Transparency
Nine women from across the U.S. share their personal experiences with breast augmentation and reconstruction with Natrelle® – celebrating confidence, self-expression, and restoration. IRVINE, Calif.
AbbVie (ABBV) Q2 2025 Earnings Call Transcript
The Big 3: ABBV, ETSY, VRT
Mike Shorr (@ProsperTradingAcademy) walks through a pair of stocks he sees set up for a swing breakout: AbbVie (ABBV) and Etsy Inc. (ETSY). For both, he demonstrates an example options trade using a c...
AbbVie Raises 2025 Outlook After Q2 Beat
AbbVie (ABBV) Lifts Full-Year EPS Guidance Following Strong Q2
AbbVie (ABBV) Lifts Full-Year EPS Guidance Following Strong Q2
If You'd Invested $1,000 in AbbVie (ABBV) Stock 10 Years Ago, Here's How Much You'd Have Today
Spoiler: You would have done well -- and even better if you'd reinvested your dividends.
Key deals this week: Chart Industries, Northwind Midstream, AbbVie, Palo Alto Networks and more
Why AbbVie Stock Flew Higher on Friday
A solid quarterly earnings report reverberated though the pundit community that day.
AbbVie Soars On Skyrizi And Rinvoq Strength, Outpacing Humira Erosion
On Thursday, AbbVie Inc. (NYSE: ABBV) reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus of $14.98 billion . Sales increased 6.6% on a reported basis or 6.5% on a...
AbbVie Soars On Skyrizi And Rinvoq Strength, Outpacing Humira Erosion
On Thursday, AbbVie Inc. ABBV reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus of $14.98 billion.
5 Dividend Stocks With Solid Returns And More Growth Ahead
Sector by sector, U.S. dividend stocks have outperformed so far this year, with historically dividend-friendly industries surpassing those with a more growth-oriented focus.
Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges
Measures laid out in letters to 17 companies would either have modest impact or face legal challenges, say industry experts.
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...
President Trump demands drugmakers slash prices within 60 days
CNBC's Joe Kernen reports on the latest news.
Donald Trump's crackdown at pharma: 'Americans need lower drug prices'; sets 29 September deadline or face action
Donald Trump has issued a stern warning to major pharmaceutical companies, demanding they drastically reduce prescription drug prices in the US. In letters to firms like AbbVie, Trump insisted on impl...
Why AbbVie Stock Slumped Today
An encouraging quarterly earnings report was dampened by a new demand from President Trump.
Pharma Companies Should Immediately Cut Down Drug Prices, Trump Says
President Donald Trump demanded several pharmaceutical companies cut down their drug prices for American consumers Thursday, issuing a Sept. 29 deadline for the businesses to “end the free ride of Ame...
AbbVie raises 2025 revenue outlook to $60.5B as Skyrizi and Rinvoq drive growth
AbbVie Inc. (ABBV) Q2 2025 Earnings Call Transcript
Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days
President Donald Trump on Thursday said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days.